I've purchased ARIA shares just in the last few months so I am in the same boat as you. It was nice when it was in the $13's, but I'm a strong believer in ponatinib's potential and so will not sell until that story develops further.
I also have INCY shares which are in the red and likely to be for some time, but I see quite a bit of potential in their JAK inhibitor program so am holding on to them.
Both ARIA and INCY are down today, but so is the NASDAQ biotech index (NBI). However, this short-term volatility will mean little if ponatinib is approved.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.